Rezolute (RZLT) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T17:18:03.602Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:18:03.602Z.

Quote observation: 2026-10-06T17:15:11.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -82,935,000
Quote market capitalization: 411,649,583
Total debt · period ending 2026-06-30: 934,000
Cash · period ending 2026-06-30: 10,615,000

FMP input reference: eb6c183c54b52a3f5be7b88cd35f52a8db6123751fb387d2cb2c86d403628cdc

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

RZLT EBITDA Yield Metrics

EBITDA YIELD

N/A

RZLT Competitors' EBITDA Yield

RZLT

Rezolute, Inc.

Current

Market Cap

$411.65M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRTA

Prothena Corporation plc

vs RZLT

Market Cap

$411.76M

EBITDA Yield

N/A

TTM Avg

6.82%

3Y Avg

6.82%

5Y Avg

6.82%

SRTA

Strata Critical Medical, Inc.

vs RZLT

Market Cap

$410.19M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SI

Shoulder Innovations, Inc.

vs RZLT

Market Cap

$409.99M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVIR

Atea Pharmaceuticals, Inc.

vs RZLT

Market Cap

$407.34M

EBITDA Yield

N/A

TTM Avg

951.70%

3Y Avg

394.96%

5Y Avg

394.96%

EIKN

Eikon Therapeutics, Inc. Common Stock

vs RZLT

Market Cap

$403.87M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MYGN

Myriad Genetics, Inc.

vs RZLT

Market Cap

$413.54M

EBITDA Yield

N/A

TTM Avg

3.45%

3Y Avg

4.91%

5Y Avg

6.50%

NGNE

Neurogene Inc.

vs RZLT

Market Cap

$406.04M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CARL

Carlsmed, Inc.

vs RZLT

Market Cap

$406.41M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SENS

Senseonics Holdings, Inc.

vs RZLT

Market Cap

$419.42M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Rezolute, Inc. (RZLT)	$411.65M	N/A	N/A	N/A	N/A
Prothena Corporation plc (PRTA)vs ›	$411.76M	N/A	6.82%	6.82%	6.82%
Strata Critical Medical, Inc. (SRTA)vs ›	$410.19M	N/A	N/A	N/A	N/A
Shoulder Innovations, Inc. (SI)vs ›	$409.99M	N/A	N/A	N/A	N/A
Atea Pharmaceuticals, Inc. (AVIR)vs ›	$407.34M	N/A	951.70%	394.96%	394.96%
Eikon Therapeutics, Inc. Common Stock (EIKN)vs ›	$403.87M	N/A	N/A	N/A	N/A
Myriad Genetics, Inc. (MYGN)vs ›	$413.54M	N/A	3.45%	4.91%	6.50%
Neurogene Inc. (NGNE)vs ›	$406.04M	N/A	N/A	N/A	N/A
Carlsmed, Inc. (CARL)vs ›	$406.41M	N/A	N/A	N/A	N/A
Senseonics Holdings, Inc. (SENS)vs ›	$419.42M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

RZLT EBITDA Yield Metrics

RZLT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics